Martin Braddock serves as a Senior Principal Scientist in respiratory and inflammation research in the UK. He is the Science Lead on a Global Product Development Team for the FosD (syk kinase inhibitor) rheumatology product in phase III clinical development in late 2010. He serves also as a Leader of the Global Biology Network across all research sites in AstraZeneca. Formerly Director of Discovery Bioscience and based in Loughborough, UK, he was the Drug Discovery Project Leader for the P2X7 receptor antagonist project which delivered 8 compounds to candidate selection, two compounds into clinical development, the most advanced to the end of phase IIb. He joined AstraZeneca from Glaxo SmithKline in 2000 where he was the Head of the Disease Sciences Unit and Leader of the Wound Healing and Tissue Regeneration Group. He has worked in a number of therapeutic areas in addition to respiratory and inflammation, which include CNS, cardiovascular and virology. He has represented inflammation projects from within emerging product teams and both inflammation and respiratory strategic direction from within Discovery. Braddock has published extensively and is a member of numerous scientific advisory boards and on the editorial committee of seven scientific journals.
Biography Updated on 30 October 2010